Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Increase in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 74,418 shares, an increase of 286.3% from the November 30th total of 19,264 shares. Based on an average trading volume of 172,559 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the shares of the company are sold short. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 172,559 shares, the short-interest ratio is currently 0.4 days.

Institutional Trading of Xtant Medical

A number of large investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in Xtant Medical during the second quarter worth approximately $26,000. Mink Brook Asset Management LLC grew its position in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after acquiring an additional 60,997 shares during the last quarter. Crescent Grove Advisors LLC increased its holdings in shares of Xtant Medical by 94.3% in the 2nd quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after acquiring an additional 200,000 shares during the period. Vanguard Group Inc. raised its position in Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 104,159 shares during the last quarter. Finally, AWM Investment Company Inc. purchased a new stake in Xtant Medical in the 2nd quarter valued at $4,875,000. 69.33% of the stock is owned by institutional investors and hedge funds.

Xtant Medical Stock Down 0.3%

Shares of NYSEAMERICAN XTNT traded down $0.00 during mid-day trading on Friday, hitting $0.78. The company had a trading volume of 46,235 shares, compared to its average volume of 240,487. The company has a market capitalization of $108.64 million, a PE ratio of 77.68 and a beta of -0.05. The business’s 50-day simple moving average is $0.73 and its 200 day simple moving average is $0.67. Xtant Medical has a 1-year low of $0.34 and a 1-year high of $0.95. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.21 and a quick ratio of 1.06.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its earnings results on Monday, November 10th. The medical device company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to analysts’ expectations of $32.70 million. Xtant Medical had a net margin of 1.32% and a return on equity of 3.77%.

Analyst Ratings Changes

Separately, BTIG Research reduced their target price on Xtant Medical from $2.00 to $1.50 and set a “buy” rating for the company in a research note on Tuesday, November 11th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Xtant Medical has an average rating of “Buy” and an average price target of $1.50.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.